MedTrace Logo

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

NCT06688656 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-11-14

No results posted yet for this study

Summary

This study is a prospective, single-arm, single-center Phase II trial, aiming to investigate efficacy and safety of neoadjuvant chemotherapy sequentially combined with sintilimab in resectable EGFR-mutant stage II-IIIB non-squamous NSCLC patients

Conditions

Interventions

DRUG

Pemetrexed 500 mg/m2

1\. Pemetrexed: 500mg/m² on Day 1, Q3W, administered via intravenous infusion for a total of 3 cycles.

DRUG

carboplatin

AUC=5 on Day 1, Q3W，administered via intravenous infusion for a total of 3 cycles.

DRUG

Sintilimab

Sintilimab, 200mg, administered via intravenous infusion on the 3rd day of each cycle, Q3W, for a total of 3 cycles.

Sponsors & Collaborators

  • Shanghai Chest Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2026-03-31
Completion
2028-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06688656 on ClinicalTrials.gov